![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
SODIUM GLUCOSE CO-TRANSPORTER-2 INHIBITORS - OVERVIEW
Anteneh Tamirat*, Jagdish Kakadiya and Shiv Kumar Rathod
ABSTRACT
Type 2 Diabetes mellitus (T2DM) is characterized by an increase in blood glucose level due to the resistance of pancreatic hormone; insulin secretion and action. Cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) have attained epidemic proportions worldwide, becoming increasingly alarming public health problems. A growing body of evidence suggests that there is a strong links or relationship between T2DM, CVD and hypertension. Sodium–glucose co transporter-2 (SGLT-2) is a new molecular target to directly induce glucose excretion and to safely normalize plasma glucose in type 2 diabetes. The SGLT-2 protein is a high capacity molecule responsible for the majority of glucose reuptake with pharmacological inhibition, resulting in the loss of about 80g of glucose in the urine each day. Sodium–glucose co transporter-2 (SGLT-2) inhibitors have a unique mechanism of action, which is independent of insulin secretion and insulin action. This unique mechanism of action, in addition to lowering plasma glucose, corrects a number of metabolic and hemodynamic abnormalities that are risk factors for CVD. Keywords: Type-2 diabetes mellitus, SGLT-2 inhibitor, Cardiac complication. [Download Article] [Download Certifiate] |